The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy

Am J Surg. 2006 Jul;192(1):58-62. doi: 10.1016/j.amjsurg.2005.12.005.

Abstract

Background: Germline mutations of BRCA1 and BRCA2 increase the risk for breast cancer. Mutation carriers selecting breast-conservation therapy (BCT) for treatment of operable breast cancer experience a higher rate of new primary breast cancers. We sought to determine the frequency of BRCA1/BRCA2 mutations in women who underwent BCT. Genetic testing results were compared with the prior probability of mutations in either gene.

Methods: Eighty-nine patients age 39 or younger entered the study. Genetic testing was performed for BRCA1 and BRCA2 and the BRCAPRO model determined the probability of carrying a mutation.

Results: Eight mutations were discovered (prevalence, 9.0%). Twenty (22%) uncharacterized sequence variants were found. The prior probability of carrying a mutation was 14%. Mutation carriers had a higher prior probability (.49) compared with women with uncharacterized variants (.09) or with normal genes (.11).

Conclusions: BRCA1 and BRCA2 mutations are common (9%) among unselected young breast cancer patients undergoing BCT.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • BRCA1 Protein / genetics*
  • BRCA2 Protein / genetics*
  • Biomarkers, Tumor / genetics*
  • Breast Neoplasms / epidemiology
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / surgery
  • DNA, Neoplasm / genetics*
  • Female
  • Follow-Up Studies
  • Genes, BRCA1
  • Germ-Line Mutation*
  • Humans
  • Mastectomy, Segmental*
  • Prevalence
  • Prognosis
  • Retrospective Studies

Substances

  • BRCA1 Protein
  • BRCA2 Protein
  • Biomarkers, Tumor
  • DNA, Neoplasm